Ratings by Credit Suisse (Judah C. Frommer)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/3/2023 | Sarepta Therapeutics | SRPT | Maintain | Neutral (N/A) |
|
Details | ||
| 5/24/2023 | Sarepta Therapeutics | SRPT | Maintain | Neutral (N/A) |
|
Details | ||
| 5/24/2023 | PTC Therapeutics | PTCT | Maintain | Neutral (N/A) |
|
Details | ||
| 5/15/2023 | Sarepta Therapeutics | SRPT | Maintain | Neutral (N/A) |
|
Details | ||
| 5/10/2023 | eFFECTOR Therapeutics, Inc. | EFTR | Maintain | Outperform (N/A) |
|
Details | ||
| 5/3/2023 | Sarepta Therapeutics | SRPT | Maintain | Neutral (N/A) |
|
Details | ||
| 4/28/2023 | PTC Therapeutics | PTCT | Maintain | Neutral (N/A) |
|
Details | ||
| 3/31/2023 | Avidity Biosciences | RNA | Maintain | Outperform (N/A) |
|
Details | ||
| 3/31/2023 | Candel Therapeutics Inc. | CADL | Maintain | Outperform (N/A) |
|
Details | ||
| 3/17/2023 | Sarepta Therapeutics | SRPT | Maintain | Neutral (N/A) |
|
Details | ||
| 3/9/2023 | eFFECTOR Therapeutics, Inc. | EFTR | Maintain | Outperform (N/A) |
|
Details | ||
| 3/7/2023 | Stoke Therapeutics | STOK | Maintain | Outperform (N/A) |
|
Details | ||
| 3/1/2023 | Sarepta Therapeutics | SRPT | Maintain | Neutral (N/A) |
|
Details | ||
| 2/28/2023 | uniQure BV | QURE | Maintain | Outperform (N/A) |
|
Details | ||
| 2/27/2023 | Fulcrum Therapeutics | FULC | Maintain | Outperform (N/A) |
|
Details | ||
| 2/15/2023 | Sarepta Therapeutics | SRPT | Maintain | Neutral (N/A) |
|
Details | ||
| 1/11/2023 | Stoke Therapeutics | STOK | Maintain | Outperform (N/A) |
|
Details | ||
| 1/10/2023 | Sarepta Therapeutics | SRPT | Maintain | Neutral (N/A) |
|
Details | ||
| 1/10/2023 | PTC Therapeutics | PTCT | Maintain | Neutral (N/A) |
|
Details | ||
| 1/6/2023 | eFFECTOR Therapeutics, Inc. | EFTR | Maintain | Outperform (N/A) |
|
Details | ||
| 12/15/2022 | Avidity Biosciences | RNA | Maintain | Outperform (N/A) |
|
Details | ||
| 12/7/2022 | Candel Therapeutics Inc. | CADL | Maintain | Outperform (N/A) |
|
Details | ||
| 11/15/2022 | Stoke Therapeutics | STOK | Maintain | Outperform (N/A) |
|
Details | ||
| 11/9/2022 | Avidity Biosciences | RNA | Maintain | Outperform (N/A) |
|
Details | ||
| 11/9/2022 | Fulcrum Therapeutics | FULC | Maintain | Outperform (N/A) |
|
Details | ||
| 11/8/2022 | Inhibrx Inc. | INBX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/3/2022 | Sarepta Therapeutics | SRPT | Maintain | Neutral (N/A) |
|
Details | ||
| 10/28/2022 | PTC Therapeutics | PTCT | Maintain | Neutral (N/A) |
|
Details | ||
| 8/10/2022 | eFFECTOR Therapeutics, Inc. | EFTR | Maintain | Outperform (N/A) |
|
Details | ||
| 8/9/2022 | Inhibrx Inc. | INBX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/8/2022 | Stoke Therapeutics | STOK | Maintain | Outperform (N/A) |
|
Details | ||
| 8/8/2022 | uniQure BV | QURE | Maintain | Outperform (N/A) |
|
Details | ||
| 8/5/2022 | PTC Therapeutics | PTCT | Maintain | Neutral (N/A) |
|
Details | ||
| 8/3/2022 | Sarepta Therapeutics | SRPT | Maintain | Neutral (N/A) |
|
Details | ||
| 6/24/2022 | Sarepta Therapeutics | SRPT | Maintain | Neutral (N/A) |
|
Details | ||
| 6/21/2022 | PTC Therapeutics | PTCT | Maintain | Neutral (N/A) |
|
Details | ||
| 5/23/2022 | PTC Therapeutics | PTCT | Maintain | Neutral (N/A) |
|
Details | ||
| 5/12/2022 | Candel Therapeutics Inc. | CADL | Maintain | Outperform (N/A) |
|
Details | ||
| 5/11/2022 | Stoke Therapeutics | STOK | Maintain | Outperform (N/A) |
|
Details | ||
| 5/11/2022 | Avidity Biosciences | RNA | Maintain | Outperform (N/A) |
|
Details | ||
| 5/11/2022 | eFFECTOR Therapeutics, Inc. | EFTR | Maintain | Outperform (N/A) |
|
Details | ||
| 5/11/2022 | Cortexyme Inc. | CRTX | Maintain | Underperform (N/A) |
|
Details | ||
| 5/9/2022 | Fulcrum Therapeutics | FULC | Maintain | Outperform (N/A) |
|
Details | ||
| 5/5/2022 | Insmed | INSM | Maintain | Outperform (N/A) |
|
Details | ||
| 5/3/2022 | uniQure BV | QURE | Maintain | Outperform (N/A) |
|
Details | ||
| 3/25/2022 | Fulcrum Therapeutics | FULC | Maintain | Outperform (N/A) |
|
Details | ||
| 3/17/2022 | eFFECTOR Therapeutics, Inc. | EFTR | Maintain | Outperform (N/A) |
|
Details | ||
| 2/25/2022 | uniQure BV | QURE | Maintain | Outperform (N/A) |
|
Details | ||
| 1/25/2022 | eFFECTOR Therapeutics, Inc. | EFTR | Maintain | Outperform (N/A) |
|
Details | ||
| 11/10/2021 | Inhibrx Inc. | INBX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/29/2021 | PTC Therapeutics | PTCT | Maintain | Neutral (N/A) |
|
Details | ||
| 10/12/2021 | eFFECTOR Therapeutics, Inc. | EFTR | New Coverage | Outperform (N/A) |
11.84 (1.78) |
-84.97% | Details | |
| 10/12/2021 | Flexion Therapeutics | FLXN | Downgrade | Neutral (Outperform) |
5.78 (9.12) |
57.79% | Details | |
| 8/23/2021 | Candel Therapeutics Inc. | CADL | New Coverage | Outperform (N/A) |
5.75 (5.46) |
-5.04% | Details | |
| 8/10/2021 | Fulcrum Therapeutics | FULC | Maintain | Outperform (N/A) |
|
Details | ||
| 8/10/2021 | Avidity Biosciences | RNA | Maintain | Outperform (N/A) |
|
Details | ||
| 8/3/2021 | Esperion Therapeutics | ESPR | Maintain | Outperform (N/A) |
|
Details | ||
| 7/27/2021 | uniQure BV | QURE | Maintain | Outperform (N/A) |
|
Details | ||
| 6/24/2021 | Fulcrum Therapeutics | FULC | Maintain | Outperform (N/A) |
|
Details | ||
| 5/13/2021 | Flexion Therapeutics | FLXN | Maintain | Outperform (N/A) |
|
Details | ||
| 5/5/2021 | Esperion Therapeutics | ESPR | Maintain | Outperform (N/A) |
|
Details | ||
| 4/26/2021 | Stoke Therapeutics | STOK | New Coverage | Outperform (N/A) |
31.58 (11.65) |
-63.11% | Details | |
| 4/26/2021 | Sarepta Therapeutics | SRPT | New Coverage | Neutral (N/A) |
70.94 (116.55) |
64.29% | Details | |
| 4/26/2021 | Avidity Biosciences | RNA | New Coverage | Outperform (N/A) |
22.48 (23.04) |
2.49% | Details | |
| 4/26/2021 | uniQure BV | QURE | New Coverage | Outperform (N/A) |
32.28 (4.71) |
-85.41% | Details | |
| 4/26/2021 | PTC Therapeutics | PTCT | New Coverage | Neutral (N/A) |
45.75 (24.69) |
-46.03% | Details | |
| 4/26/2021 | Insmed | INSM | New Coverage | Outperform (N/A) |
35.00 (24.80) |
-29.14% | Details | |
| 4/26/2021 | Inhibrx Inc. | INBX | New Coverage | Outperform (N/A) |
18.98 (34.45) |
81.51% | Details | |
| 4/26/2021 | Fulcrum Therapeutics | FULC | New Coverage | Outperform (N/A) |
11.45 (7.06) |
-38.34% | Details | |
| 4/26/2021 | Flexion Therapeutics | FLXN | New Coverage | Outperform (N/A) |
8.16 (9.12) |
11.76% | Details | |
| 4/26/2021 | Esperion Therapeutics | ESPR | New Coverage | Outperform (N/A) |
27.51 (9.14) |
-66.78% | Details | |
| 4/26/2021 | Cortexyme Inc. | CRTX | New Coverage | Underperform (N/A) |
38.26 (1.95) |
-94.9% | Details | |
| 4/26/2021 | Satsuma Pharmaceuticals | STSA | New Coverage | Neutral (N/A) |
5.24 (1.10) |
-79.01% | Details |
